New York State Common Retirement Fund X4 Pharmaceuticals, Inc Transaction History

New York State Common Retirement Fund

$73.9 Billion
Q3 2024

A detailed history of New York State Common Retirement Fund transactions in X4 Pharmaceuticals, Inc stock. As of the latest transaction made, New York State Common Retirement Fund holds 51,639 shares of XFOR stock, worth $17,557. This represents 0.0% of its overall portfolio holdings.

Number of Shares

51,639

Previous 51,639 -0.0%

Holding current value

$17,557

Previous $30,000 16.67%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 31, 2024	BUY	$0.58 - $1.47 $51 - $129	88 Added 0.17%	51,639 $30,000
Q4 2023 Feb 01, 2024	SELL	$0.61 - $0.99 $254 - $412	-417 Reduced 0.8%	51,551 $43,000
Q3 2023 Nov 07, 2023	BUY	$1.03 - $2.02 $1,409 - $2,763	1,368 Added 2.7%	51,968 $57,000
Q2 2023 Aug 07, 2023	BUY	$0.82 - $2.49 $41,492 - $125,994	50,600 New	50,600 $98,000
Q3 2021 Nov 02, 2021	SELL	$4.53 - $6.45 $607 - $864	-134 Closed	0 $0
Q2 2021 Aug 02, 2021	SELL	$6.49 - $9.56 $43,917 - $64,692	-6,767 Reduced 98.06%	134 $1,000
Q3 2020 Nov 05, 2020	SELL	$6.09 - $9.15 $48,720 - $73,200	-8,000 Reduced 53.69%	6,901 $47,000
Q2 2020 Aug 07, 2020	BUY	$7.98 - $10.44 $85,386 - $111,708	10,700 Added 254.7%	14,901 $139,000
Q1 2020 May 06, 2020	SELL	$6.03 - $11.01 $50,235 - $91,724	-8,331 Reduced 66.48%	4,201 $42,000
Q4 2019 Feb 05, 2020	BUY	$9.93 - $14.33 $52,629 - $75,949	5,300 Added 73.29%	12,532 $134,000
Q2 2019 Aug 09, 2019	BUY	$12.57 - $21.67 $80,435 - $138,666	6,399 Added 768.19%	7,232 $108,000
Q1 2019 May 08, 2019	BUY	$15.19 - $22.98 $12,653 - $19,142	833 New	833 $14,000

Others Institutions Holding XFOR

# of Institutions

105

Shares Held

100M

Call Options Held

213K

Put Options Held

50.6K

View Full List

About X4 Pharmaceuticals, Inc

Ticker XFOR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,646,096
Market Cap $23.3M
Description
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase...

More about XFOR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of New York State Common Retirement Fund, based on Form 13F filings with the SEC.

News

Stay updated on New York State Common Retirement Fund with notifications on news.

Account

New York State Common Retirement Fund X4 Pharmaceuticals, Inc Transaction History